Tag - 4T1乳腺癌模型

  • Home
  • Tag -
  • 4T1乳腺癌模型
Fig 1 CD4+ T cells play a crucial role in immune checkpoint inhibitor treatment against tumor growth. Tumor growth of (A) MB49 (n = 7), EMT-6 (n = 5), CT26WT (n = 7) and Hepa1-6 (n = 5) tumors with or without anti-CTLA-4 Ab treatment (n = 7). The average tumor volume is shown as the mean ± standard error of the mean (SEM). * P < 0.05, ** P < 0.01, *** P < 0.001 by Mann-Whitney test at the endpoint. (B, C) Tumor growth of Hepa1-6 or Hepa1-6#12 tumors with or without anti-CTLA-4 Ab co-administered with a depleting Ab against CD4+ or CD8+ T cells. These depletion Abs were injected via intraperitoneal administration starting 2 days prior to tumor cell injection and continued weekly. The average tumor volume is shown as the mean ± SEM (n = 7–8). * P < 0.05, ** P < 0.01, *** P < 0.001 by one-way ANOVA followed by Dunnett’s test at the endpoint.
Figure 1 The effect of anti-PD-1 and anti-CTLA-4 antibodies on the tumor growth in B16-F10-bearing mice. (A) A schematic diagram illustrating the chronological events of experiments (n=8). (B) Tumor growth kinetics in anti-PD-1 day 1-4-7, anti-PD-1 day 11-14-17 or anti-CTLA-4 day 1-4-7 treated B16-F10-bearing mice, compared with vehicle (n=2). Data are mean ± SEM. (C,D,E,F,G,H) The correlation of tumor size and tumor-infiltrating and splenic immune cell population infiltrating CD45+CD3+ (C), CD45+CD3+CD8+ T cells (D), CD45+CD3+CD4+ T cells (E) and CD45+CD11b+ myeloid cells (F), splenic CD45+CD3+CD8+ (G) and CD45+CD3+CD4+ T cells (H). VE, vehicle; PD1, anti-PD-1 day 1-4-7; PD11, anti-PD-1 day 11-14-17; CT, anti-CTLA-4 day 1-4-7; PD-1, programmed cell death-1; CTLA-4, cytotoxic T-lymphocyte-associated protein 4.
Figure 4 CTLA-4 blockade is less effective in aged mice. CT26 tumor cells were subcutaneously implanted on the flank of female BALB/c mice either at 6-8 weeks old (young) or at 60-72 weeks old (aged). (A, B) The mice were treated with anti-CTLA-4 antibody IP at 10 mg/kg twice weekly starting 7 days after tumor cell implantation for a total of 6 doses. (A) Kaplan-Meier curves showing time-to-welfare endpoint. 38 mice per group. (B) Fold change in rate of tumor growth for each animal in both young and aged mice after anti-CTLA-4 antibody treatment compared to age-matched untreated mice. 38 mice per group. (C, D) The mice were treated IP at 10 mg/kg twice weekly for a total of 6 doses with a combination of anti-PD-L1 antibody (starting 4 days after tumor cell implantation) and anti-CTLA-4 antibody (starting 7 days after tumor cell implantation). (C) Kaplan-Meier curves showing time-to-welfare endpoint. 37-38 mice per group. (D) Fold change in rate of tumor growth for each animal in both young and aged mice after anti-PD-L1 and anti-CTLA-4 antibodies compared to age-matched untreated mice. 37-38 mice per group. The results in panels (A, B) include data from 3 experiments and the results in panels (C, D) include data from 4 experiments. ns, non-significant, *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001.
Fig 1 CD4+ T cells play a crucial role in immune checkpoint inhibitor treatment against tumor growth. Tumor growth of (A) MB49 (n = 7), EMT-6 (n = 5), CT26WT (n = 7) and Hepa1-6 (n = 5) tumors with or without anti-CTLA-4 Ab treatment (n = 7). The average tumor volume is shown as the mean ± standard error of the mean (SEM). * P < 0.05, ** P < 0.01, *** P < 0.001 by Mann-Whitney test at the endpoint. (B, C) Tumor growth of Hepa1-6 or Hepa1-6#12 tumors with or without anti-CTLA-4 Ab co-administered with a depleting Ab against CD4+ or CD8+ T cells. These depletion Abs were injected via intraperitoneal administration starting 2 days prior to tumor cell injection and continued weekly. The average tumor volume is shown as the mean ± SEM (n = 7–8). * P < 0.05, ** P < 0.01, *** P < 0.001 by one-way ANOVA followed by Dunnett’s test at the endpoint.

9D9抗体在不同小鼠肿瘤模型中剂量建议

9D9抗体（抗小鼠CTLA-4单抗）在小鼠肿瘤模型和其他小鼠模型中通常用于体内CTLA-4中和、肿瘤内调节性T细胞耗竭等研究。那么，9D9抗体在不同小鼠肿瘤模型中的注射剂量如何确定？欢迎参考本文。

2025年10月16日产品新闻, 新闻, 资讯, , , , , , , , , , , , , , , , , Read more...
a Group mean TV from treatment initiation on Day 10 through end of study on Day 34. n = 10 mice/group. All animals survived through Day 34 with exception of one animal in untreated group which exited study on Day 32. SPD suspensions (40 mg/mL) and vehicle were dosed IT on Days 10, 14, 18, and 22 (red triangles). Anti-mCTLA-4 (10 mg/kg) was dosed IP on Days 10, 13, 17, and 20 (black diamonds). The combination group received both SPD and anti-mCTLA-4 on the same schedules as the monotreatments. b Group mean percent change in body weight from treatment initiation on Day 10 through end of study on Day 34. Error bars =  ± SEM. Significance reported for Day 34 versus untreated/vehicle controls; ns not significant, *p 

抗小鼠CTLA-4单抗(9D9)在4T1乳腺癌模型中剂量建议

抗小鼠CTLA-4单抗（9D9）在小鼠肿瘤模型和其他小鼠模型中通常用于体内CTLA-4中和、肿瘤内调节性T细胞耗竭等研究。那么，9D9抗体在4T1乳腺癌模型中的注射剂量怎么确定？欢迎参考本文。

2025年10月16日产品新闻, 新闻, 资讯, , , , , , , Read more...

10F.9G2抗体在不同小鼠肿瘤模型中剂量建议

10F.9G2抗体（抗小鼠PD-L1单抗）在小鼠肿瘤模型和其他小鼠模型中通常用于阻断体内PD-L1信号传导。那么，10F.9G2抗体在不同小鼠肿瘤模型中的注射剂量如何确定？欢迎参考本文。

2025年10月14日产品新闻, 新闻, 资讯, , , , , , , , , , , , , , , , , , , , Read more...

抗小鼠PD-L1单抗(10F.9G2)在4T1乳腺癌模型中剂量建议

抗小鼠PD-L1单抗（10F.9G2）在小鼠肿瘤模型和其他小鼠模型中通常用于阻断体内PD-L1信号传导。那么，10F.9G2抗体在4T1乳腺癌模型中的注射剂量如何确定？欢迎参考本文。

2025年10月14日产品新闻, 新闻, 资讯, , , , , , , Read more...

RMP1-14抗体在不同小鼠肿瘤模型中剂量建议

RMP1-14抗体（抗小鼠PD-1单抗）在小鼠肿瘤模型和其他小鼠模型中通常用于阻断体内PD-1信号传导。那么，RMP1-14抗体在不同小鼠肿瘤模型中的注射剂量如何确定？欢迎参考本文。

2025年10月13日产品新闻, 新闻, 资讯, , , , , , , , , , , , , , , , , , , Read more...

抗小鼠PD-1单抗(RMP1-14)在4T1乳腺癌模型中剂量建议

抗小鼠PD-1单抗（RMP1-14）在小鼠肿瘤模型和其他小鼠模型中通常用于阻断体内PD-1信号传导。那么，RMP1-14抗体在4T1乳腺癌模型中的注射剂量如何确定？欢迎参考本文。

2025年10月12日产品新闻, 新闻, 资讯, , , , , , , Read more...